Lunai Bioworks announces early results from AI-based platform

Lunai Bioworks (LNAI) (RENB) announced early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase, the same molecular target affected by nerve agents. “This research brings us closer to a future where proactive, AI-powered screening can detect and evaluate neurotoxic compounds before they become threats,” said David Weinstein, CEO. “Our vision is to use in vivo systems like zebrafish, combined with predictive AI, to rapidly identify neurotoxic threats and screen for countermeasures, and leverage our AI models to help safeguard against the creation of new neurotoxins.” Using a combination of chemical feature analysis and machine learning classifiers, Lunai’s platform demonstrated an ability to differentiate active AChE inhibitors from inactive compounds with high accuracy. The work builds on models trained using the company’s in-house neuroactive compound screening data, as well as public sources, and applies predictive modeling to identify chemical signatures associated with AChE inhibition. Compounds with previously unidentified, potential neurotoxic activity have been identified for follow-up and validation. In future phases, the company plans to integrate its behavioral zebrafish profiling platform to observe real-time physiological effects of predicted inhibitors, helping prioritize candidate compounds for further development as potential countermeasures.